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Lumping, Splitting, and Sorting
Frank C. Detterbeck, MD
A staging system is an evolutionary process, and it requires periodic revision. This issuereports the proposed latest revision of the lung cancer staging system with respect to
the definition of the T component.1 Distinct strengths of this revision are the remarkable
size of the database that has been compiled, the sophistication of the analysis, and the
attention to validation of the proposed new definitions. It is based on 100,869 patients,
gleaned from multiple registries, centers, and series representing Europe, North America,
Asia, and Australia, and it includes patients with all stages and histologic types of lung
cancer. In contrast, the previous iteration of the staging system was based on 5319 patients
who were exclusively from North America; it included few patients with SCLC, and it
underrepresented nonsurgical patients.
The purposes of a staging system are to establish a common terminology, to define
prognosis, to define cohorts with similar treatment strategies, and, lastly, to group patients
by the biologic behavior of their tumors. The primary focus chosen by the staging
committee is prognostication; therefore, the emphasis is on postresection pathologic
classification. Nevertheless, clinicians will want to use this system to guide clinical
management decisions, most of which are made before treatment. We must be careful in
extrapolating the data from the pathologic stage to the pretreatment situation. What we
would really like, of course, is to predict a tumor’s biologic behavior and group patients
accordingly. Unfortunately, our ability to do this is limited, although there is hope that the
evolving genetic characterization of tumors will provide this.
It is good that the proposed T staging system emphasizes tumor size, because this
can be easily determined before treatment. Nevertheless, because treatment strategies also
evolve, it will be important to keep track of details in addition to the T classification. For
example, adjuvant chemotherapy trials should record the actual size of the tumors—not
just whether they are T2a or T2b.
The issue of the underlying biologic behavior is best illustrated by the difficulties in
trying to classify an additional focus of cancer in the lung parenchyma separate from the
primary mass. A reasonable amount of data suggest that an additional focus in the same
lobe represents a form of local spread2; indeed, prognosis and treatment strategy are not
altered in a major way by a same-lobe satellite nodule. A second focus in a different lobe,
nevertheless, is more problematic. Is this evidence of field cancerization (a second
primary), an unusual form of intrapulmonary spread, or a solitary distant metastasis that
happens to be in the lung? Understanding this would have significant implications for the
treatment. Simply grouping according to observed prognosis (which may be highly
dependent on the treatment strategy chosen) may be purely arbitrary and misleading.
Furthermore, this area is complicated by the possibility of ethnic and environmental
differences. The incidence of separate foci of cancer seems to be higher in Asia, and it may
represent a different tumor biology than on other continents (i.e., higher incidence of
adenocarcinoma or a higher rate of response of endothelial growth factor receptor
inhibitors). Again, authors reporting results in these patients should detail specific
subgroups rather than pooling all T4 patients together, so that we can learn how we should
be thinking about these patients.
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Grouping patients purely by prognosis is problematic
because it is a moving target. As treatments evolve, outcomes
change. Furthermore, it is becoming increasingly clear that a
diagnosis of lung cancer is not a black and white matter; there
are shades of gray along a spectrum of biologic aggressive-
ness. Importantly, the spectrum of disease identified (and,
therefore, the prognosis) changes as technology advances.
Lung cancers that are associated with 10- and 20-year sur-
vival without treatment are being recognized,3 perhaps be-
cause of a proliferation of computed tomography imaging.
We must be careful to develop systems that can adjust to
changes, because the pace of change can only be expected to
increase.
Like any good scientific study, the proposed staging
revision leaves at least as many questions open to future
investigation as it answers. What is the best size criterion to
distinguish between T1 and T2 subgroups? Should this be
based on the overall size or on the size of the solid compo-
nents in patients with a ground-glass periphery? Should the T
classification be the same for different tumor types, and
should it be the same for patients on different continents? The
proposed classification system is particularly strong because
it is derived from an international cohort and because it has
been internally and externally validated. It gives us a com-
mon language to speak. But we must be careful to go beyond
the system in describing populations that are potentially
grouped more arbitrarily. As our knowledge evolves, partic-
ularly with molecular genetic analysis, we may define dis-
tinctions that are not yet clearly apparent. I look forward to
challenges and refinements as the thoracic oncology commu-
nity deliberates the proposed new staging classification.
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